Author

Longyong Xu

The University of Texas MD Anderson Cancer CenterORCID 0000-0002-8574-4062Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Bryan Latrell HollomaniD· 1 shared Dong LuiD· 1 shared Feng JiniD· 1 shared Hanfeng LiniD· 1 shared Jin WangiD· 1 shared Lang DingiD· 1 shared Meng Carla WangiD· 1 shared Rishi R. PaudeliD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

Bryan Latrell HollomanORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity

Xin Yu, Dong Lu, Xiaoli Qi, Rishi R. Paudel, Hanfeng Lin, Bryan Latrell Holloman, Feng Jin, Longyong Xu, Lang Ding, Weiyi Peng, Meng Carla Wang, Xi Chen, Jin Wang

This paper develops a first-in-class RIPK1 degrader, LD4172, which enhances antitumor immunity by promoting immunogenic cell death and sensitizing tumors to anti-PD1 therapy.

Nature Communications · Dec 16, 2024Peer-reviewedPharmacology & Toxicology